June 3, 2013

Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds

 

Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds

Paris, France – June 3, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studies of its investigational compounds iniparib and otamixaban respectively.